Biopharma AI
By
Is Novartis Deepening Its Bet on AI-Enabled Molecular Glue Degraders Through an Expanded Collaboration With Monte Rosa?
Novartis AG (SIX: NOVN; NYSE: NVS), a global leader in immunology and targeted therapies, has broadened its partnership…
Can DeepMind’s Demis Hassabis Slash Drug Discovery Timelines From Years to Months—And What Does That Mean for Pharma Startups?
Key Highlights: What Hassabis Says: A Turning Point for Drug DiscoveryDemis Hassabis, CEO of DeepMind, recently told Bloomberg…
Is Lilly’s “TuneLab” the Breakthrough AI Collaboration Model Biotech Startups Have Been Waiting For?
Key Highlights A bold move: Lilly democratizes AI for biotechEli Lilly has launched TuneLab, a novel AI platform…
Can AI-Powered Platforms from Certara, Recursion, and Charles River Cut Drug Development Timelines by 50% as FDA Pushes Beyond Animal Testing?
Key Takeaways FDA’s New Roadmap Sparks Industry Transformation The U.S. FDA has outlined a bold strategy to make…
Is Biopharma’s $8.5 Billion AI Investment in 2025 Across Discovery, R&D, and Commercialization Shaping the 2026 Innovation Landscape?
Global – December 31, 2025 — Biopharmaceutical companies significantly increased investment in artificial intelligence (AI) in 2025, allocating…
What Does SoftBank’s $41 Billion Bet on OpenAI Signal for the Future of Biopharma, Healthcare, and AI Infrastructure?
Global – December 2025 — SoftBank’s $41 billion investment in OpenAI represents one of the most consequential capital…
